TerminatedPhase 2NCT02689219
Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors
Studying Embryonal carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Nabil Adra
- Principal Investigator
- Costantine Albany, MDIndiana University School of Medicine, Indiana University Simon Cancer Center
- Intervention
- Brentuximab Vedotin(drug)
- Enrollment
- 18 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2016 – 2019
Study locations (4)
- USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Indiana University Health Hospital, Indianapolis, Indiana, United States
- Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02689219 on ClinicalTrials.govOther trials for Embryonal carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT04086485Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)National Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGNCT05168631Multicenter Retrospective Database on Prognostic and Predictive Factors in Patients With Neuroendocrine TumorsLatin American Cooperative Oncology Group
- RECRUITINGNCT02688894The Molecular Screening Study for the Umbrella Trial (SUKSES) in Relapsed Small Cell Lung Cancer Patients [SUKSES-S]Samsung Medical Center
- RECRUITINGPHASE1, PHASE2NCT02174549Dose-defining Study of Tirapazamine Combined With Embolization in Liver CancerTeclison Ltd.
- RECRUITINGNANCT01980264Harmonics-based in Vivo Optical Virtual BiopsyNational Taiwan University Hospital